Compare EIX & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EIX | INSM |
|---|---|---|
| Founded | 1886 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.8B | 22.4B |
| IPO Year | 1994 | 2000 |
| Metric | EIX | INSM |
|---|---|---|
| Price | $71.32 | $123.69 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 24 |
| Target Price | $72.09 | ★ $201.17 |
| AVG Volume (30 Days) | 3.0M | ★ 3.1M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 5.17% | N/A |
| EPS Growth | ★ 248.94 | N/A |
| EPS | ★ 1.37 | N/A |
| Revenue | ★ $19,317,000,000.00 | N/A |
| Revenue This Year | N/A | $182.31 |
| Revenue Next Year | $3.17 | $65.19 |
| P/E Ratio | $51.59 | ★ N/A |
| Revenue Growth | ★ 9.76 | N/A |
| 52 Week Low | $52.00 | $90.39 |
| 52 Week High | $81.62 | $212.75 |
| Indicator | EIX | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 44.26 | 59.38 |
| Support Level | $67.48 | $95.24 |
| Resistance Level | $72.89 | $140.30 |
| Average True Range (ATR) | 2.26 | 4.84 |
| MACD | -0.44 | 2.19 |
| Stochastic Oscillator | 30.32 | 65.82 |
Edison International is the parent company of Southern California Edison, an electric utility that distributes electricity to 5 million customers in a 50,000-square-mile area of Southern California, excluding Los Angeles. Edison Energy owns interests in nonutility businesses that deal in energy-related products and services. In 2014, Edison International sold its wholesale power generation subsidiary Edison Mission Energy out of bankruptcy to NRG Energy.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.